European Journal of Pharmaceutical Sciences,
Год журнала:
2025,
Номер
207, С. 107041 - 107041
Опубликована: Фев. 12, 2025
Heat
shock
protein
90
(Hsp90)
is
a
pivotal
virulence
factor
in
pathogenic
fungi,
playing
significant
role
conferring
drug
resistance.
However,
due
to
the
high
amino
acid
sequence
similarity
between
fungal
and
mammalian
Hsp90,
targeting
intracellular
Hsp90
therapeutically
associated
with
marked
toxic
side
effects,
thereby
limiting
clinical
application.
Studies
have
demonstrated
that
can
be
secreted
as
extracellular
(eHsp90),
which
plays
crucial
infections.
Strategies
eHsp90
exhibited
promising
therapeutic
outcomes.
Unlike
targeting,
such
antifungal
approaches
operate
without
cell
penetration,
circumventing
effects
Hsp90's
conservation.
This
review
summarizes
potential
secretion
pathways
of
eHsp90,
its
roles
pathogenesis,
well
development
vaccines
antibodies
eHsp90.
The
underlines
significance
infections
suggests
represents
target
for
infection
treatment.
ACS Infectious Diseases,
Год журнала:
2024,
Номер
10(8), С. 3059 - 3070
Опубликована: Июль 12, 2024
Invasive
fungal
diseases
(IFDs)
are
becoming
increasingly
acknowledged
as
a
significant
concern
linked
to
heightened
rates
of
morbidity
and
mortality.
Regrettably,
the
available
antifungal
therapies
for
managing
IFDs
constrained.
Emerging
evidence
indicates
that
enolase
holds
promise
potential
target
protein
combating
IFDs;
however,
there
is
currently
deficiency
in
medications
specifically
targeting
enolase.
This
study
establishes
isobavachalcone
(IBC)
exhibits
noteworthy
efficacy
both
vitro
vivo.
Moreover,
our
has
demonstrated
IBC
effectively
targets
Eno1
Advanced Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 12, 2024
Abstract
Candidiasis,
which
presents
a
substantial
risk
to
human
well‐being,
is
frequently
treated
with
azoles.
However,
drug‐drug
interactions
caused
by
azoles
inhibiting
the
CYP3A4
enzyme,
together
increasing
resistance
of
Candida
species
azoles,
represent
serious
issues
this
class
drug,
making
it
imperative
develop
innovative
antifungal
drugs
tackle
growing
clinical
challenge.
A
drug
repurposing
approach
used
examine
library
Food
and
Drug
Administration
(FDA)‐approved
drugs,
ultimately
identifying
otilonium
bromide
(OTB)
as
an
exceptionally
encouraging
agent.
Mechanistically,
OTB
impairs
vesicle‐mediated
trafficking
targeting
Sec31,
thereby
impeding
plasma
membrane
(PM)
localization
ergosterol
transporters,
such
Sip3.
Consequently,
obstructs
movement
across
membranes
triggers
cytotoxic
autophagy.
It
noteworthy
that
C.
albicans
encounters
challenges
in
developing
because
not
substrate
for
transporters.
This
study
opens
new
door
therapy,
wherein
disrupts
subcellular
distribution
induces
Additionally,
circumvents
hepatotoxicity
associated
azole‐mediated
liver
enzyme
inhibition
avoids
export‐mediated
.
European Journal of Pharmaceutical Sciences,
Год журнала:
2025,
Номер
207, С. 107041 - 107041
Опубликована: Фев. 12, 2025
Heat
shock
protein
90
(Hsp90)
is
a
pivotal
virulence
factor
in
pathogenic
fungi,
playing
significant
role
conferring
drug
resistance.
However,
due
to
the
high
amino
acid
sequence
similarity
between
fungal
and
mammalian
Hsp90,
targeting
intracellular
Hsp90
therapeutically
associated
with
marked
toxic
side
effects,
thereby
limiting
clinical
application.
Studies
have
demonstrated
that
can
be
secreted
as
extracellular
(eHsp90),
which
plays
crucial
infections.
Strategies
eHsp90
exhibited
promising
therapeutic
outcomes.
Unlike
targeting,
such
antifungal
approaches
operate
without
cell
penetration,
circumventing
effects
Hsp90's
conservation.
This
review
summarizes
potential
secretion
pathways
of
eHsp90,
its
roles
pathogenesis,
well
development
vaccines
antibodies
eHsp90.
The
underlines
significance
infections
suggests
represents
target
for
infection
treatment.
